ANTI-HUMAN-HER3 ANTIBODIES AND USES THEREOF

The present disclosure relates to a neuregulin non competitive allosteric anti-human-HER3 antibody comprising (a) a heavy chain wherein the variable domain comprises: a H-CDR1 having a sequence set forth as SEQ ID NO: 2; a H-CDR2 having a sequence set forth as SEQ ID NO: 3;and a H-CDR3 having a sequence set forth as SEQ ID NO: 4; and (b) a light chain wherein the variable domain comprises at least a CDR having a sequence chosen from the group consisting of SEQ ID NO: 6 as L-CDR1, SEQ ID NO: 7 as L-CDR2 and SEQ ID NO: 8 as L-CDR3; said antibody having a human constant region; and less than 65 % of the glycan structures carried by the glycosylation site of the antibody comprise a fucose molecule. A nucleic acid sequence encoding it, as well as a host cell, an immunoconjugate comprising it, a pharmaceutical composition comprising it as well as their pharmaceutical use are also considered.